Cagrilintide

Long-acting amylin analog. In combination with semaglutide (CagriSema) shows >25% weight loss.

✅ Potential Benefits

Amylin receptor agonism — complements GLP-1 action
In combo with semaglutide: >25% weight loss in trials
Reduces food intake through satiety signaling
Slows gastric emptying
Improves glucose metabolism
Weekly injection — convenient

💊 Dosing Protocol

0.3–2.4mg SubQ weekly (dose escalation). Often combined with semaglutide.

⏱ Half-Life

~7–8 days

⚠️ Common Side Effects

Nausea, vomiting, injection site reactions, decreased appetite.

🚫 Warnings & Contraindications

Still in late-stage clinical trials — not yet approved
GI side effects can be significant
Combination with semaglutide amplifies both efficacy and side effects
Do not combine with other amylin analogs

🚨 Adverse Effects

GI effects similar to GLP-1 agonists. Hypoglycemia risk in diabetics.

📬 Interested in Cagrilintide?

Have questions about this peptide or want to discuss availability?

✉️ Send an Inquiry

⚕️ This information is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before beginning any wellness protocol.

Track your Cagrilintide protocol in the app

Calculate exact doses, schedule injections, journal your progress.

🚀 Try Free for 7 Days